| _version_ | 1866902043482914816 |
|---|---|
| author | Tahir, Bhatti Tahir, Bhatti Tahir, Bhatti |
| author_facet | Tahir, Bhatti Tahir, Bhatti Tahir, Bhatti |
| contents | <p><strong>Introduction</strong></p> <p>GVAtlas (Genomic Variants Atlas) is an innovative genomic surveillance platform developed by Tahir Hussain Bhatti (MSc. Molecular Biology) to track, analyze, and visualize SARS CoV 2 variants through a proprietary Variant Impact Scoring (VIS) system, a novel methodology absent in existing tools like Nextclade. Coined in 2020, GVAtlas and its VIS framework represent original contributions to genomic analysis, formalized here for the first time as a public record (Zenodo, June 20, 2025).</p> <p><strong>Key Functionalities</strong></p> <p>Proprietary Variant Impact Scoring (VIS):</p> <p>Original Work:</p> <p>Introduced by Tahir Hussain Bhatti in <strong>2020</strong>, <strong>VIS</strong> is a first of its kind scoring system that quantifies the functional and clinical significance of SARS CoV 2 mutations, addressing gaps in tools limited to lineage tracking (e.g., Nextclade).</p> <p><strong>ACE2 Binding Affinity Score:</strong></p> <p>Scale: 0.0–1.0+ (Low/Moderate/High).</p> <p><strong>Example:</strong> OY550408 (XBB.1.5.13) scores 1.012, indicating high transmissibility.</p> <p><strong>Basis:</strong> Structural modeling and binding energy datasets.</p> <p><strong>Immune Escape Score:</strong></p> <p>Scale: 0.0–1.0+ (Low/Moderate/High).</p> <p><strong>Example: </strong>OY550408 scores 0.948, signaling high evasion potential.</p> <p>Basis: Epitope mapping and neutralization assays.</p> <p>Differentiator:</p> <p>Unlike Nextclade’s descriptive mutation lists, VIS provides actionable, standardized metrics to prioritize variants for research and public health response.</p> <p><strong>Claim to Originality</strong></p> <p>The term "<strong>GVAtlas</strong>" and its Variant Impact Scoring (VIS) system were conceptualized and developed solely by Tahir Hussain Bhatti, beginning in 2020. No existing platform (including Nextclade, GISAID, or NCBI tools) offers an equivalent scoring framework for mutation impact. This submission asserts priority over the name, methodology, and intellectual property of VIS, positioning GVAtlas as a transformative advance in genomic surveillance.</p> <p><strong>Future Directions</strong></p> <p>I will refine VIS via machine learning and experimental validation.</p> <p>I will Expand VIS to other pathogens, reinforcing GVAtlas’s role as a global standard for variant impact assessment.</p> <p> </p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_15707746 |
| institution | Zenodo |
| language | eng |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | GVAtlas: Pioneering Genomic Variant Analysis and Visualization for SARS CoV 2 and Beyond Tahir, Bhatti Tahir, Bhatti Tahir, Bhatti SARS-CoV-2 COVID-19 Genomic Surveillance Variant Tracking Mutation Analysis Co-infection Genomics GVAtlas Variant Impact Scoring (VIS) Viral Evolution Public Health Genomics Underserved Regions Functional Genomics Comparative Genomics Sequence Annotation Emerging Variants Next-Generation Sequencing Viral Genomics Respiratory Viruses Cross-Variant Analysis Genomic Variants Atlas <p><strong>Introduction</strong></p> <p>GVAtlas (Genomic Variants Atlas) is an innovative genomic surveillance platform developed by Tahir Hussain Bhatti (MSc. Molecular Biology) to track, analyze, and visualize SARS CoV 2 variants through a proprietary Variant Impact Scoring (VIS) system, a novel methodology absent in existing tools like Nextclade. Coined in 2020, GVAtlas and its VIS framework represent original contributions to genomic analysis, formalized here for the first time as a public record (Zenodo, June 20, 2025).</p> <p><strong>Key Functionalities</strong></p> <p>Proprietary Variant Impact Scoring (VIS):</p> <p>Original Work:</p> <p>Introduced by Tahir Hussain Bhatti in <strong>2020</strong>, <strong>VIS</strong> is a first of its kind scoring system that quantifies the functional and clinical significance of SARS CoV 2 mutations, addressing gaps in tools limited to lineage tracking (e.g., Nextclade).</p> <p><strong>ACE2 Binding Affinity Score:</strong></p> <p>Scale: 0.0–1.0+ (Low/Moderate/High).</p> <p><strong>Example:</strong> OY550408 (XBB.1.5.13) scores 1.012, indicating high transmissibility.</p> <p><strong>Basis:</strong> Structural modeling and binding energy datasets.</p> <p><strong>Immune Escape Score:</strong></p> <p>Scale: 0.0–1.0+ (Low/Moderate/High).</p> <p><strong>Example: </strong>OY550408 scores 0.948, signaling high evasion potential.</p> <p>Basis: Epitope mapping and neutralization assays.</p> <p>Differentiator:</p> <p>Unlike Nextclade’s descriptive mutation lists, VIS provides actionable, standardized metrics to prioritize variants for research and public health response.</p> <p><strong>Claim to Originality</strong></p> <p>The term "<strong>GVAtlas</strong>" and its Variant Impact Scoring (VIS) system were conceptualized and developed solely by Tahir Hussain Bhatti, beginning in 2020. No existing platform (including Nextclade, GISAID, or NCBI tools) offers an equivalent scoring framework for mutation impact. This submission asserts priority over the name, methodology, and intellectual property of VIS, positioning GVAtlas as a transformative advance in genomic surveillance.</p> <p><strong>Future Directions</strong></p> <p>I will refine VIS via machine learning and experimental validation.</p> <p>I will Expand VIS to other pathogens, reinforcing GVAtlas’s role as a global standard for variant impact assessment.</p> <p> </p> |
| title | GVAtlas: Pioneering Genomic Variant Analysis and Visualization for SARS CoV 2 and Beyond |
| topic | SARS-CoV-2 COVID-19 Genomic Surveillance Variant Tracking Mutation Analysis Co-infection Genomics GVAtlas Variant Impact Scoring (VIS) Viral Evolution Public Health Genomics Underserved Regions Functional Genomics Comparative Genomics Sequence Annotation Emerging Variants Next-Generation Sequencing Viral Genomics Respiratory Viruses Cross-Variant Analysis Genomic Variants Atlas |
| url | https://doi.org/10.5281/zenodo.15707746 |